Gao, Teng http://orcid.org/0000-0002-0196-689X
Ptashkin, Ryan
Bolton, Kelly L.
Sirenko, Maria http://orcid.org/0000-0001-7816-8071
Fong, Christopher
Spitzer, Barbara
Menghrajani, Kamal
Ossa, Juan E. Arango
Zhou, Yangyu
Bernard, Elsa http://orcid.org/0000-0002-2057-7187
Levine, Max http://orcid.org/0000-0001-5156-9086
Martinez, Juan S. Medina
Zhang, Yanming
Franch-ExpĆ³sito, SebastiĆ http://orcid.org/0000-0002-4542-1701
Patel, Minal
Braunstein, Lior Z.
Kelly, Daniel
Yabe, Mariko
Benayed, Ryma http://orcid.org/0000-0002-3754-0321
Caltabellotta, Nicole M.
Philip, John http://orcid.org/0000-0002-0535-7178
Paraiso, Ederlinda
Mantha, Simon
Solit, David B. http://orcid.org/0000-0002-6614-802X
Diaz, Luis A. Jr
Berger, Michael F. http://orcid.org/0000-0003-3882-5000
Klimek, Virginia
Levine, Ross L. http://orcid.org/0000-0002-7884-1905
Zehir, Ahmet http://orcid.org/0000-0001-5406-4104
Devlin, Sean M.
Papaemmanuil, Elli http://orcid.org/0000-0003-1709-8983
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA254130-01)
V Foundation for Cancer Research
Damon Runyon Cancer Research Foundation
Article History
Received: 24 July 2020
Accepted: 1 December 2020
First Online: 12 January 2021
Competing interests
: The authors declare the following competing interests: K.L.B. has received research funding from GRAIL; E.B. receives research funding from Celgene. D.B.S. has served as a consultant/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina, and Vivideon Therapeutics. M.F.B has participated in advisory board activities for Roche and has received research support from Grail and Illumina. S.M.D. is principal owner of Daboia Consulting LLC. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. He is a paid consultant to PGDx and Neophore. He is an uncompensated consultant for Merck but has received travel and research support for clinical trials from Merck. L.A.D. is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and L.A.D. His wife holds equity in Amgen. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. J.S.M.M. is a member of the board of directors and holds equity in Isabl, a software analytics company for high-throughput clinical whole-genome and RNA-sequencing analyses. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis which include equity interest. He receives research support from and consulted for Celgene and Roche, and has consulted for Lilly, Janssen, Astellas, Morphosys, and Novartis. He has received honoraria from Roche, Lilly, and Amgen for invited lectures and from Gilead for grant reviews. A.Z. received honoraria from Illumina. E. Papaemmanuil receives research funding from Celgene and has received honoraria for speaking and scientific advisory engagements with Celgene, Prime Oncology, Novartis, Illumina, and Kyowa Hakko Kirin. E. Papaemmanuil is also a member of the board of directors and holds equity in Isabl, a software analytics company for high-throughput clinical whole-genome and RNA-sequencing analyses. E. Papaemmanuil is an inventor in software licenses related to technology of genome analytics. Some of these licenses and relationships are associated with equity or royalty payments to MSKCC and are managed accordingly by the conflict of interest office at MSKCC. The remaining authors declare no competing interests.